MIRA Pharmaceuticals, Inc.

What they do

MIRA Pharmaceuticals is a development-stage company that has not generated any revenues. Its operations are primarily focused on advancing its product candidates through pre-clinical and clinical development, with no approved products or commercial sales. As of the latest balance sheet, the company holds mostly cash and short-term related-party investments, indicating limited operational scale.

Revenue drivers

• No current revenue streams — The company has not generated any revenue from product sales or other sources; its financials show net losses each year from 2022 through 2025.

Recent performance

For the quarter ended June 30, 2026, MIRA reported cash of $3.6 million, down from $6.3 million at December 31, 2025. Total assets were $8.2 million, with total liabilities of $40,823. Annual net income has been negative for all reported years, with a net loss of $10.4 million in 2025. Operating cash flow has been consistently negative, around -$5 million annually. The company's auditor included a going concern explanatory paragraph in the fiscal 2025 audited financial statements.

Strategy

MIRA is prioritizing the advancement of its product candidates through pre-clinical and clinical trials. The company relies on external funding to support its operations and development activities, as indicated by its ongoing need for additional financing. Management focuses on obtaining regulatory approval for its candidates and building intellectual property protection. The company has also entered into material agreements and maintains a relationship with MIRALOGX, which could present conflicts of interest.

Risks

• Going concern uncertainty — The company's auditor has raised substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flow.
• No revenues — MIRA has not generated any revenue and expects to continue incurring losses for the foreseeable future, which may require additional funding.
• Limited operating history — As an early development-stage company, its limited history makes it difficult to evaluate operations and predict future performance.
• Dependence on related-party financing — The company holds short-term investments with a related party and has had advances payable to a related party, creating potential conflicts of interest.

Outlook

Management expects to continue incurring significant expenses related to research and development, requiring additional financing to fund operations. The company will need to raise capital to support its product development plans and address its liquidity needs. Regulatory approval of product candidates and successful clinical trials are key to its future prospects.